Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Data confirm combination therapy improves breast cancer survival in fit women
December 1st, 2005
New data confirm that the Xeloda (capecitabine) and Taxotere (docetaxel) combination improves survival time by an important 3 months in younger or fitter women with an aggressive form of breast cancer that has spread to other parts of the body (metastatic). This is the first study designed to show that taking the two potent drugs together improves women's survival when compared to the more commonly used 'sequential treatment' approach of taking Taxotere alone followed by Xeloda alone. The study noted a slight increase in the known manageable side effects of the two drugs, but this is more than compensated by the prospect of increased survival. These...
Source: Women's Health Weekly (2005-12-01)
|
